PD-1 blockade with nivolumab in endemic Kaposi sarcoma

Affiliations

¹ Dermatology Department, AP-HP Hôpital Saint Louis, Paris, France; Université Paris VII Diderot, Sorbonne Paris Cité, Paris, France; INSERM U976, Paris, France. Electronic address: julie.delyon@aphp.fr.
² Dermatology Department, AP-HP Hôpital Saint Louis, Paris, France.
³ Université Paris VII Diderot, Sorbonne Paris Cité, Paris, France; Pathology Department, AP-HP Hôpital Saint Louis, Paris, France; INSERM U1165, AP-HP Hôpital Saint Louis, Paris, France.
⁴ Department of Pharmacy, AP-HP Hôpital Saint Louis, Paris, France.
⁵ Department of Nuclear Medicine, AP-HP Hôpital Saint Louis, Paris, France.
⁶ Dermatology Department, AP-HP Hôpital Saint Louis, Paris, France; Université Paris VII Diderot, Sorbonne Paris Cité, Paris, France; INSERM U976, Paris, France.

Free article

Case Reports

J Delyon et al. Ann Oncol. 2018.

Free article

. 2018 Apr 1;29(4):1067-1069.

doi: 10.1093/annonc/mdy006.

¹ Dermatology Department, AP-HP Hôpital Saint Louis, Paris, France; Université Paris VII Diderot, Sorbonne Paris Cité, Paris, France; INSERM U976, Paris, France. Electronic address: julie.delyon@aphp.fr.
² Dermatology Department, AP-HP Hôpital Saint Louis, Paris, France.
³ Université Paris VII Diderot, Sorbonne Paris Cité, Paris, France; Pathology Department, AP-HP Hôpital Saint Louis, Paris, France; INSERM U1165, AP-HP Hôpital Saint Louis, Paris, France.
⁴ Department of Pharmacy, AP-HP Hôpital Saint Louis, Paris, France.
⁵ Department of Nuclear Medicine, AP-HP Hôpital Saint Louis, Paris, France.
⁶ Dermatology Department, AP-HP Hôpital Saint Louis, Paris, France; Université Paris VII Diderot, Sorbonne Paris Cité, Paris, France; INSERM U976, Paris, France.

No abstract available

Publication types